HEPION PHARMACEUTICALS, INC. Proceeds from Issuance of Debt
HEPION PHARMACEUTICALS, INC. (HEPA) reported Proceeds from Issuance of Debt of $176.59 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2021-03-31
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2020-12-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2020-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2019-12-31 was $0.00.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2019-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2020 was $176.59K, a 85.87% decline from fiscal 2019.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2019 was $1.25M, a 37.50% decline from fiscal 2018.
- HEPION PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2018 was $2.00M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $0.00 derived: sum of 2 quarters · filed 2021-03-31 | $176.59K 10-K · filed 2021-03-31 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $176.59K 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $176.59K 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $0.00 derived: sum of 2 quarters · filed 2021-03-31 | $1.25M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $1.25M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $1.25M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14 | $0.00 derived: sum of 2 quarters · filed 2020-05-14 | $2.00M 10-K · filed 2020-05-14 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $2.00M 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | $2.00M 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |